Company press releases

Viser 51 - 65 av 65 resultater
Tid Selskap Tittel Sektor Kategori
18 Sep 2023
08:00 CEST 		OXURION Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC 20103010 Biotechnology -
11 Sep 2023
08:00 CEST 		OXURION Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 20103010 Biotechnology -
07 Sep 2023
19:00 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
01 Sep 2023
19:00 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
01 Sep 2023
19:00 CEST 		OXURION Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC 20103010 Biotechnology -
25 Aug 2023
22:00 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
23 Aug 2023
20:05 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
23 Aug 2023
20:00 CEST 		OXURION Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC 20103010 Biotechnology -
21 Aug 2023
19:05 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
21 Aug 2023
19:00 CEST 		OXURION Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC 20103010 Biotechnology -
16 Aug 2023
19:00 CEST 		OXURION Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC 20103010 Biotechnology -
11 Aug 2023
08:08 CEST 		OXURION Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program 20103010 Biotechnology -
11 Aug 2023
08:05 CEST 		OXURION Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas 20103010 Biotechnology -
11 Aug 2023
08:00 CEST 		OXURION Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC 20103010 Biotechnology -
19 Jul 2019
12:21 CEST 		OXURION Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Biotechnology Products and services